(PharmaNewsWire.Com, August 19, 2019 ) The growth in this market is driven by the need for early disease detection and diagnosis, the increased focus on human microbiome therapy, and the growing demand for human microbiomes as new validated targets for drug development.
Major Growth Restraints:
# Lack of Expertise and Detailed Research
# Barriers in Proving the Causal Link Between Dysbiosis and Disease
Opportunities:
# Investigational New Drug (IND) Requirements for Fecal Microbiota
Based on disease, the human microbiome market is segmented into obesity, diabetes, autoimmune disorders, acute diarrhea, cancer, mental disorders, and other diseases. The acute diarrhea segment is expected to account for the largest share of the market in 2022, primarily due to the increasing use of microbiome-based products for diarrhea indications.
Based on application, the human microbiome market is segmented into therapeutic and diagnostic applications. The diagnostic applications segment is expected to register the highest growth during the forecast period. Factors such as the development of automated instruments with high-throughput capabilities, advances in life science research, and the development of molecular diagnostics such as cancer diagnostics are contributing to the growth of this segment.
Europe is expected to command as a resourceful market with the largest share in the market and expected to grow within the coming years. This is due to Europe’s aging population size and the increasing lifestyle diseases, followed by the increasing need to stay fit and have a healthy lifestyle has leveraged the use of prebiotics and probiotics. APAC accounted for the second-largest market share and will be the main focus of the human microbiome market in the coming five years that will register high-growth rates for all the segments.
Enterome Bioscience (France), Yakult (Japan), DuPont (U.S.), Metabiomics Corporation (U.S.), ViThera Pharmaceuticals (U.S.), Second Genome Inc. (U.S.), MicroBiome Therapeutics LLC (U.S.), Vedanta BioSciences (U.S.), Osel, Inc. (U.S.), and Merck (U.S.) are the major players in the human microbiome market. Domination of the individual segments in this market will depend on the core competencies of different players.
Companies that launch products targeted at specific indications in the human microbiome market are likely to maintain their positions in this market. Pfizer is one such company; it releases medicines and vaccines for specific indications. The firm also entered into an agreement with Second Genome for microbiome research in obesity and metabolic disorders.
Companies in the human microbiome market are majorly focusing on expanding and entering segments for new indications and technology. The key strategy is to expand market share through acquisitions and connect financially with firms having common values and goals. To gain maximum market share, companies have been aggressively signing agreements, collaborations, and partnerships with third-party vendors.
Enterome Bioscience is one such company the company focuses on developing biomarkers, companion diagnostic kits, and therapeutic solutions. The company provides products and technologies in the emerging areas of disease management for human gut microbiome and drugs for the treatment of various microbiome-related diseases, such as inflammatory bowel disease, metabolic diseases, and related disorders.
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
